Optimal control for therapeutic drug treatment on a delayed model incorporating immune response

dc.contributor.authorDubey, Balram
dc.contributor.authorDubey, Uma S.
dc.date.accessioned2023-07-27T09:23:39Z
dc.date.available2023-07-27T09:23:39Z
dc.date.issued2016
dc.description.abstractMillions of people get infected every year by viral pathogens. Newly emergent diseases such as Ebola, Swine-flu, HIV/AIDS, etc. are spreading worldwide at an alarming rate. We introduced a delayed mathematical model with immune response and therapeutic drug treatment to understand the dynamics of pathogenimmune interaction. Here, we are considering the innate immune response and the two major component of the acquired immune response, namely, cytotoxic T lymphocytes (CTLs) and humoral immunity. This model also incorporates the absorption of pathogens i.e. loss of pathogens and its related mechanisms. Further, an optimal control model is formulated with two optimal controls i.e. maximization of uninfected cells count and minimization of cost of treatments. This is done by using the Pontryagins' Maximum Principle. Existence of non-negative equilibria is established and their stability behavior is studied using theory of ordinary differential equations. Further, numerical simulations are carried out to exemplify the qualitative results.en_US
dc.identifier.urihttps://www.worldscientific.com/doi/abs/10.1142/9789813141919_0015
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/11039
dc.language.isoenen_US
dc.publisherWorld Scientificen_US
dc.subjectMathematicsen_US
dc.subjectTherapeuticen_US
dc.subjectImmune responseen_US
dc.titleOptimal control for therapeutic drug treatment on a delayed model incorporating immune responseen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: